Hedgehog pathway

Hedgehog pathway
Name	Hedgehog pathway
Organism	Drosophila melanogaster, Mus musculus, Homo sapiens
Discovered	1980s
Discoverer	Christiane Nüsslein-Volhard, Eric Wieschaus
Key components	Sonic hedgehog, Patched, Smoothened, Gli proteins
Functions	Embryonic patterning, stem cell maintenance, organogenesis

Hedgehog pathway The Hedgehog pathway is a conserved intercellular signaling cascade central to metazoan embryogenesis and postnatal tissue maintenance. First revealed through genetic screens in Drosophila melanogaster by Christiane Nüsslein-Volhard and Eric Wieschaus, the pathway's components have since been studied across model organisms including Caenorhabditis elegans, Danio rerio, Mus musculus, and Homo sapiens. Research on this pathway intersects with work at institutions such as the Howard Hughes Medical Institute, Cold Spring Harbor Laboratory, and Max Planck Society.

Introduction

The pathway was identified during mutational analyses in Drosophila melanogaster segmentation mutants by Christiane Nüsslein-Volhard and Eric Wieschaus, leading to insights also recognized by the Nobel Prize in Physiology or Medicine. Subsequent characterization involved investigators at laboratories like the Salk Institute, Harvard University, and University of Cambridge. Hedgehog signaling is mediated by secreted ligands (notably Sonic hedgehog) that influence cell fate decisions in tissues such as the neural tube, limb bud, and somite. Classic developmental phenotypes studied by groups working on Zebrafish and Mouse knockouts informed our understanding of morphogen gradients and dose-dependent patterning in organs including the limb and brain.

Components and Molecular Mechanism

Core ligands include Sonic hedgehog (Shh), Indian hedgehog (Ihh), and Desert hedgehog (Dhh), each characterized in molecular genetics laboratories at institutions like Stanford University and Yale University. Receptors and transducers central to the cascade include Patched (Ptch) and Smoothened (Smo), with downstream transcriptional mediators the Gli family (Gli1, Gli2, Gli3). Primary cilia, studied in the context of ciliopathy research at centers such as Johns Hopkins University and Mount Sinai Health System, serve as signaling hubs for vertebrate transduction. Biochemical work involving laboratories at the European Molecular Biology Laboratory delineated cholesterol modification of ligands, proteolytic processing of Gli proteins, and the inhibitory relief that Smo experiences upon Ptch binding. Structural biology investigations at facilities such as the European Synchrotron Radiation Facility and Argonne National Laboratory have resolved Smo conformations and ligand interactions, informing models of pathway activation and repression.

Roles in Development and Tissue Patterning

Hedgehog signaling patterns the dorsoventral axis of the neural tube and establishes anterior–posterior polarity of the limb bud, processes examined in classic experiments from the University of California, Berkeley and University College London. Shh from the notochord and floor plate induces motor neuron identity; this developmental role has been studied in collaboration between groups at the Massachusetts Institute of Technology and Cold Spring Harbor Laboratory. Ihh regulates chondrocyte differentiation within the growth plate, a topic of investigation at pediatric research centers such as the Children's Hospital of Philadelphia. Dhh is essential for peripheral nerve sheath development, a subject explored at the National Institutes of Health. Spatial and temporal gradients of ligand concentration function as morphogens, a concept grounded in experiments tied to researchers affiliated with the Max Planck Institute for Developmental Biology.

Regulation and Crosstalk with Other Pathways

Hedgehog signaling integrates with multiple signaling networks, including interactions with the Wnt signaling pathway, Notch signaling pathway, Bone morphogenetic protein, and Fibroblast growth factor cascades. Crosstalk mechanisms have been mapped in cancer biology centers such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute, where pathway interplay affects tumor microenvironment and stem cell niches. Post-translational modifications, including ubiquitination mediated by E3 ligases characterized at Cold Spring Harbor Laboratory and phosphorylation events reported by Cambridge University laboratories, modulate Gli stability. Negative and positive feedback loops involving transcriptional targets like Gli1 and Ptch1 contribute to signal robustness, as described in systems biology studies at the Scripps Research Institute and Imperial College London.

Implications in Disease and Cancer

Aberrant Hedgehog signaling is implicated in congenital malformations such as holoprosencephaly and limb patterning defects documented by clinical genetics groups at Great Ormond Street Hospital and Boston Children's Hospital. Constitutive pathway activation underlies cancers including basal cell carcinoma, medulloblastoma, and subsets of pancreatic adenocarcinoma and small cell lung carcinoma, studied extensively at oncology centers like MD Anderson Cancer Center and Royal Marsden Hospital. Mutations in PTCH1, SMO, and SUFU have been cataloged in databases curated by institutions such as the National Cancer Institute and Cancer Research UK. Ciliopathies that perturb Hedgehog transduction connect to syndromes researched at the European Reference Network for rare diseases.

Therapeutic Targeting and Inhibitors

Pharmacologic inhibition of Smoothened has produced clinically approved agents like vismodegib and sonidegib, developed through collaborations involving Genentech, Novartis, and academic partners at the University of California, San Francisco. Resistance mechanisms involving downstream Gli activation and secondary SMO mutations have been reported by investigators at Vanderbilt University and Stanford University, prompting efforts to target Gli transcriptional activity and ligand secretion in trials sponsored by groups such as National Cancer Institute cooperative networks. Emerging strategies include monoclonal antibodies, small molecules disrupting protein–protein interactions, and RNA-based therapeutics explored at biotechnology companies like Regeneron and Moderna as well as translational programs at Kings College London. Clinical trial results published by consortia including European Organisation for Research and Treatment of Cancer inform ongoing development of combination regimens to overcome resistance and minimize adverse effects such as muscle spasms and dysgeusia.

Category:Cell signaling pathways